Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00375011 · ClinicalTrials.gov registry record
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
A clinical trial, sponsored by Meridian Bioscience.
- Terminated
- Registry status
- 200
- Enrollment target
NCT00375011 is a clinical trial that was terminated before completion, run by Meridian Bioscience. The registered enrollment target is 200 participants.
The verdict
NCT00375011 was terminated before completion, sponsored by Meridian Bioscience.
- TERMINATED
- Registry status
- 200 participants
- Enrollment target
Study Summary
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2. To determine the critical value of hepatic metabolic function as measured by BreathID will predict which patients are at risk to develop complications of cirrhosis. 3. To determine the critical value of hepatic metabolic function as measured by BreathID will predict which patients are at risk for liver related mortality. The hypothesis is that the BreathID breath test will correlate to CTP and MELD scores, and that thresholds can be established that will help predict risk of complications of cirrhosis and mortality.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00375011
The ClinicalTrials.gov registry entry for NCT00375011 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00375011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00375011 about?
NCT00375011 is a clinical study titled "Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics". The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2. To determine the critical value of hepatic metabolic function as measured by BreathID will...
What is the current status of trial NCT00375011?
This trial is currently terminated. The enrollment target is 200 participants. The study started on 2008-09. Estimated completion is 2011-10.
Who is sponsoring clinical trial NCT00375011?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.